Performance Scorecard
Strong organic growth in the year across implantable devices and capital equipment with improved margin, with acquisitions providing additional opportunity for growth.
- In line with guidance provided to the market, FY15 exceeded prior corresponding period in revenue and Core EBITDA by 13.8% and 14.0% respectively.
- Organic growth strategy continues to deliver strong growth for the core segments of Spine/Neuro, Orthopaedics and Cardiology as a result of the impact of new product introductions and growth in new customers throughout FY15.
- Successful completion and integration of M4 Healthcare acquisition on 27 May 2015 providing an extension into the growing Point of Care Ultrasound market.
- Consistent with our focussed growth strategy, LifeHealthcare has also entered into a conditional agreement to acquire 100% of Medical Vision Australia Cardiology & Thoracic Pty Limited (MVA) for upfront consideration of approximately $9.0m.
- Margin was maintained through proactive management strategies including price increases, improved trading terms and management of reimbursed products.
- Improved operating cash flow increasing 54.5% from FY14 and strong conversion rate on EBITDA of 99%;
- Declaration of a final dividend of 7.5 cents per share (unfranked), giving total dividends for FY15 of 15.0 cents, representing 73% of NPATA.
For further information please download PDF attached:
